Is CGON or MAZE more profitable?

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Maze Therapeutics N/A -36.62% -31.78%

Does the media refer more to CGON or MAZE?

In the previous week, CG Oncology had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 13 mentions for CG Oncology and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat CG Oncology's score of 0.93 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ERAS or MAZE more profitable?

Erasca's return on equity of -35.31% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer ERAS or MAZE?

In the previous week, Erasca had 34 more articles in the media than Maze Therapeutics. MarketBeat recorded 40 mentions for Erasca and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Erasca's score of 0.25 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 8 Very Positive mention(s) 1 Positive mention(s) 30 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or MAZE?

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Maze Therapeutics. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Amneal Pharmaceuticals' score of 0.88 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRRK or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Maze Therapeutics N/A -36.62% -31.78%

Does the media refer more to SRRK or MAZE?

In the previous week, Scholar Rock had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Scholar Rock's score of 0.98 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DNTH or MAZE?

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Maze Therapeutics. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Maze Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.39 beat Maze Therapeutics' score of 1.11 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maze Therapeutics (MAZE) Competitors

$26.92 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.94 +1.02 (+3.79%)

As of 07/31/2026 07:58 PM Eastern

Compare

MAZE vs. CGON, ERAS, AMRX, SRRK, and DNTH

Should you buy Maze Therapeutics stock or one of its competitors? MarketBeat compares Maze Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maze Therapeutics include CG Oncology (CGON), Erasca (ERAS), Amneal Pharmaceuticals (AMRX), Scholar Rock (SRRK), and Dianthus Therapeutics (DNTH).

How does Maze Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

CG Oncology presently has a consensus price target of $81.73, suggesting a potential upside of 14.80%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 145.17%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$5.07M	1,238.24	-$160.99M	-$2.33	N/A
Maze Therapeutics	$20M	74.49	-$131.12M	-$2.53	N/A

CG Oncology has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, CG Oncology had 7 more articles in the media than Maze Therapeutics. MarketBeat recorded 13 mentions for CG Oncology and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat CG Oncology's score of 0.93 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Maze Therapeutics beats CG Oncology on 9 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Erasca has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Erasca has higher earnings, but lower revenue than Maze Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Maze Therapeutics	$20M	74.49	-$131.12M	-$2.53	N/A

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Erasca had 34 more articles in the media than Maze Therapeutics. MarketBeat recorded 40 mentions for Erasca and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Erasca's score of 0.25 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	8 Very Positive mention(s)	1 Positive mention(s)	30 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca's return on equity of -35.31% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Maze Therapeutics	N/A	-36.62%	-31.78%

Erasca currently has a consensus target price of $21.64, suggesting a potential upside of 19.21%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 145.17%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Erasca and Maze Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Maze Therapeutics' net margin of 0.00%. Maze Therapeutics' return on equity of -36.62% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Maze Therapeutics	N/A	-36.62%	-31.78%

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.94	$72.06M	$0.49	37.39
Maze Therapeutics	$20M	74.49	-$131.12M	-$2.53	N/A

Amneal Pharmaceuticals currently has a consensus target price of $17.33, suggesting a potential downside of 5.39%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 145.17%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Amneal Pharmaceuticals had 15 more articles in the media than Maze Therapeutics. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Amneal Pharmaceuticals' score of 0.88 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amneal Pharmaceuticals beats Maze Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Maze Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Scholar Rock has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

91.1% of Scholar Rock shares are held by institutional investors. 10.3% of Scholar Rock shares are held by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Scholar Rock had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 8 mentions for Scholar Rock and 6 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.11 beat Scholar Rock's score of 0.98 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics' return on equity of -36.62% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Maze Therapeutics	N/A	-36.62%	-31.78%

Maze Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Maze Therapeutics	$20M	74.49	-$131.12M	-$2.53	N/A

Scholar Rock presently has a consensus price target of $56.21, suggesting a potential upside of 18.87%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 145.17%. Given Maze Therapeutics' higher probable upside, analysts clearly believe Maze Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Maze Therapeutics beats Scholar Rock on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

47.5% of Dianthus Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 5.3% of Maze Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Dianthus Therapeutics had 4 more articles in the media than Maze Therapeutics. MarketBeat recorded 10 mentions for Dianthus Therapeutics and 6 mentions for Maze Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.39 beat Maze Therapeutics' score of 1.11 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics currently has a consensus target price of $117.82, suggesting a potential upside of 10.19%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 145.17%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Maze Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Maze Therapeutics	N/A	-36.62%	-31.78%

Maze Therapeutics has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$1.34M	4,374.92	-$162.34M	-$4.13	N/A
Maze Therapeutics	$20M	74.49	-$131.12M	-$2.53	N/A

Dianthus Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Summary

Maze Therapeutics beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.49B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-10.64	7.38	282.30	24.66
Price / Sales	74.49	1,203.55	564.25	75.48
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.65	16.95	10.98	6.07
Net Income	-$131.12M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-6.17%	-1.81%	-0.60%	-0.44%
1 Month Performance	-13.88%	-8.43%	-5.19%	-4.81%
1 Year Performance	80.67%	48.41%	62.02%	18.61%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.2864 of 5 stars	$26.92 flat	$66.00 +145.2%	+80.7%	$1.49B	$20M	N/A	121	Positive News Insider Trade
CGON CG Oncology	3.0174 of 5 stars	$69.32 -2.5%	$81.73 +17.9%	+170.6%	$6.11B	$4.04M	N/A	61	Positive News Upcoming Earnings
ERAS Erasca	2.3555 of 5 stars	$19.11 -1.2%	$21.64 +13.2%	+1,205.8%	$5.94B	N/A	N/A	120	Trending News Gap Up
AMRX Amneal Pharmaceuticals	2.8875 of 5 stars	$17.92 -0.3%	$16.60 -7.4%	+134.0%	$5.72B	$3.02B	47.16	8,500	Trending News Analyst Forecast
SRRK Scholar Rock	3.1437 of 5 stars	$47.67 -3.7%	$56.00 +17.5%	+30.1%	$5.71B	N/A	N/A	140	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. CGON, ERAS, AMRX, SRRK, and DNTH

How does Maze Therapeutics compare to CG Oncology?

Summary

How does Maze Therapeutics compare to Erasca?

Summary

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Scholar Rock?

Summary

How does Maze Therapeutics compare to Dianthus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. CGON, ERAS, AMRX, SRRK, and DNTH

How does Maze Therapeutics compare to CG Oncology?

Do analysts recommend CGON or MAZE?

Which has stronger valuation & earnings, CGON or MAZE?

Which has more risk and volatility, CGON or MAZE?

Do institutionals & insiders hold more shares of CGON or MAZE?

Is CGON or MAZE more profitable?

Does the media refer more to CGON or MAZE?

Summary

How does Maze Therapeutics compare to Erasca?

Which has more volatility and risk, ERAS or MAZE?

Which has better earnings and valuation, ERAS or MAZE?

Do insiders & institutionals hold more shares of ERAS or MAZE?

Does the media prefer ERAS or MAZE?

Is ERAS or MAZE more profitable?

Do analysts recommend ERAS or MAZE?

Summary

How does Maze Therapeutics compare to Amneal Pharmaceuticals?

Is AMRX or MAZE more profitable?

Do insiders and institutionals hold more shares of AMRX or MAZE?

Which has more volatility & risk, AMRX or MAZE?

Which has better valuation and earnings, AMRX or MAZE?

Do analysts recommend AMRX or MAZE?

Does the media favor AMRX or MAZE?

Summary

How does Maze Therapeutics compare to Scholar Rock?

Which has more risk & volatility, SRRK or MAZE?

Do insiders & institutionals hold more shares of SRRK or MAZE?

Does the media refer more to SRRK or MAZE?

Is SRRK or MAZE more profitable?

Which has preferable earnings and valuation, SRRK or MAZE?

Do analysts rate SRRK or MAZE?

Summary

How does Maze Therapeutics compare to Dianthus Therapeutics?

Do institutionals and insiders hold more shares of DNTH or MAZE?

Does the media prefer DNTH or MAZE?

Do analysts rate DNTH or MAZE?

Is DNTH or MAZE more profitable?

Which has stronger valuation and earnings, DNTH or MAZE?

Which has more volatility & risk, DNTH or MAZE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools